Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/CRD.0000000000000042 http://scihub22266oqcxt.onion/10.1097/CRD.0000000000000042 25275717!ä!25275717 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25275717.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cardiol+Rev 2015 ; 23 (1): 33-51 Nephropedia Template TP {{tp|p=25275717|t=2015. Pulmonary arterial hypertension: a review in pharmacotherapy |pdf=|usr=}}{{25275717}} gab.com Text Pulmonary arterial hypertension: a review in pharmacotherapy JO: Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=25275717 #FOAvip Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression. Twit Text FOAVip Pulmonary arterial hypertension: a review in pharmacotherapy ????Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=25275717 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25275717 #FOAvip English Wikipedia <ref>{{Cite pmid|25275717}}</ref> Pulmonary arterial hypertension: a review in pharmacotherapy #MMPMID25275717 Patel BB; Feng Y; Cheng-Lai A Cardiol Rev 2015[Jan]; 23 (1): 33-51 PMID25275717show ga Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression. |*Disease Progression[MESH] |Antihypertensive Agents/*therapeutic use[MESH] |Drug Therapy/*trends[MESH] |Epoprostenol/analogs & derivatives/therapeutic use[MESH] |Humans[MESH] |Hypertension, Pulmonary/*drug therapy/*physiopathology[MESH] |Pyrazoles/therapeutic use[MESH] |Pyrimidines/therapeutic use[MESH] |Sulfonamides/therapeutic use[MESH] |Time Factors[MESH] |Treatment Outcome[MESH]Pulmonary arterial hypertension: a review in pharmacotherapy (epmc).pdf DeepDyve Pubget Overpricing